Claret says it latest fund will have larger focus on European life sciences
European firm Claret Capital Partners has raised €575 million in its latest round, dubbed Fund IV, and a sizable portion will be lent out to local biotech companies and manufacturers. Roughly one third of the ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.